Drug Profile
Research programme: bispecific antibodies - AbbVie/F-star Therapeutics
Alternative Names: FS-29; FS-31; FS-320; FS-322Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator AbbVie; f-star
- Developer AbbVie; F-star Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)